Independent analysis was conducted by the Department of Microbiology & Immunology at the Yong Loo Lin School of Medicine, within the National University of Singapore (NUS), one of the world’s top research institutions.
Testing involved placing a solution containing MHV-A59 a coronavirus strain emerging from mice on a thin film containing Nanoveu’s antiviral technology.
This strain of virus was selected as it is a surrogate of human coronavirus 229E.
Significantly, NUS results found the number of viable or infectious coronavirus particles was reduced by 90% in 10 minutes.
Further independent test results anticipated shortly
Nanoveu executive chairman and CEO Alfred Chong said: “The Nanoveu technology is poised to revolutionise safety for all mobile phone users and the results from the National University of Singapore further validates our inherent value proposition as a timely product in today’s evolving world impacted by the COVID-19 Pandemic.
“We are thrilled to be able to demonstrate, via a highly reputable research institute, that Nanoveu’s phone protection technology can reduce active coronavirus particles by a factor of 10 in just 10 minutes.
“Further independent test results are anticipated shortly from another reputable laboratory in the United States, and we hope this analysis will be in-line with results to date.”
Significance of MHV-A59 testing
Test results from NUS on the MHV-A59 strain are considered highly significant in demonstrating the effectiveness of Nanoveu’s technology against a wide number of viruses due to a number of broad similarities in both structure and genus variety between mouse-based murine hepatitis virus (MHV-A59) and coronaviruses.
From a structural perspective, all coronaviruses exhibit a large viral envelope, which is a layer of proteins derived from former host cells that shield the viral genome when outside host environments.
Nanoveu’s technology is capable of breaking down this viral envelope, effectively killing the virus.
The company believes that the effectiveness of this method against one strain of enveloped virus suggests its technology may be effective against a whole family of viruses.
Path to market
Additional testing is ongoing at a well-regarded laboratory in the United States.
Nanoveu expects to test its technology against coronavirus OC43, which is a betacoronavirus shown to infect human hosts and is a known cause of the common cold.
The company is also investigating pathways to market with potential for pre-orders in parallel with product development and production, targeting products being available in late second quarter 2020 / early third quarter 2020.
For further information on the Nanoveu technology visit: www.nanoshield.co